BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36464833)

  • 1. Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma.
    Jagosky MH; Anderson CJ; Symanowski JT; Steuerwald NM; Farhangfar CJ; Baldrige EA; Benbow JH; Livingston MB; Patt JC; Ahrens WA; Kneisl JS; Kim ES
    Cancer Med; 2023 Mar; 12(6):7029-7038. PubMed ID: 36464833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.
    Yamashita K; Kohashi K; Yamada Y; Akatsuka S; Ikuta K; Nishida Y; Toyokuni S; Oda Y
    Genes Chromosomes Cancer; 2021 Jan; 60(1):26-37. PubMed ID: 33111425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
    Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
    Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of Fédération Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases.
    Jour G; Gullet A; Liu M; Hoch BL
    Mod Pathol; 2015 Jan; 28(1):37-47. PubMed ID: 25059573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
    Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
    Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
    Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
    Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
    Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
    Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.
    Saâda-Bouzid E; Burel-Vandenbos F; Ranchère-Vince D; Birtwisle-Peyrottes I; Chetaille B; Bouvier C; Château MC; Peoc'h M; Battistella M; Bazin A; Gal J; Michiels JF; Coindre JM; Pedeutour F; Bianchini L
    Mod Pathol; 2015 Nov; 28(11):1404-14. PubMed ID: 26336885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degree of
    Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
    Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
    Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
    Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of MDM2 Fluorescence In Situ Hybridization and Immunohistochemistry in Distinguishing Dedifferentiated Liposarcoma From Other High-grade Sarcomas.
    Song MJ; Cho KJ; Lee JS; Song JS
    Appl Immunohistochem Mol Morphol; 2017; 25(10):712-719. PubMed ID: 27028243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
    Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
    Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status.
    Makise N; Sekimizu M; Kubo T; Wakai S; Hiraoka N; Komiyama M; Fukayama M; Kawai A; Ichikawa H; Yoshida A
    Am J Surg Pathol; 2018 May; 42(5):656-664. PubMed ID: 29309298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features: a clinicopathological analysis of five cases].
    Si HP; Wang Z; Fan QH; Zhang YF; Yang DQ; Zhang ZH; Gong QX
    Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):282-287. PubMed ID: 30955263
    [No Abstract]   [Full Text] [Related]  

  • 16. Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma.
    Segura-Sánchez J; González-Cámpora R; Pareja-Megia MJ; García-Escudero A; Galera-Ruiz H; López-Beltrán A
    Anticancer Res; 2006; 26(6C):4937-42. PubMed ID: 17214366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
    Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
    BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.
    Asano N; Yoshida A; Mitani S; Kobayashi E; Shiotani B; Komiyama M; Fujimoto H; Chuman H; Morioka H; Matsumoto M; Nakamura M; Kubo T; Kato M; Kohno T; Kawai A; Kondo T; Ichikawa H
    Oncotarget; 2017 Feb; 8(8):12941-12952. PubMed ID: 28099935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of
    Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
    Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases.
    Ricciotti RW; Baraff AJ; Jour G; Kyriss M; Wu Y; Liu Y; Li SC; Hoch B; Liu YJ
    Cancer Genet; 2017 Dec; 218-219():69-80. PubMed ID: 29153098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.